Related Experiment Videos
[Pseudomyxoma peritonei. A review]
1Département de Chirurgie Générale Carcinologique, Institut Gustave Roussy, Villejuif. elias@igr.fr
Abstract:
Pseudomyxoma peritonei is a rare disease characterized by the presence of a large mucin component within the abdomen. Recent pathological and genetic advances indicate that they originate from an appendiceal adenoma or adenocarcinoma. Their prognostic is worse than ovarian border-line mucinous tumors (with which they are frequently confused). Currently, the histologic aspect permits to separate the diffuse peritoneal adenomucinosis (DPAM) originating from adenomas, with a relatively benign course, from the mucinous peritoneal carcinomatosis (MPC) originating from adenocarcinomas, with a very poor prognosis. Paradoxically, the treatment of these two diseases are rather similar, with supra-radical surgery as frequently as possible. This type of surgery allows to reach a crude 5-year survival comprised between 50% and 70%, with very different results according to the DPAM-type or the MPC-type. The adjunction of an intraperitoneal chemo-hyperthermia is logical for these two types of disease and probably increases the survival rate.
Insights
Pseudomyxoma peritonei, a rare abdominal mucin disease, originates from appendiceal tumors. Distinguishing between diffuse peritoneal adenomucinosis (DPAM) and mucinous peritoneal carcinomatosis (MPC) is crucial for prognosis and treatment strategies.
Area of Science:
- Oncology
- Gastroenterology
- Pathology
Background:
- Pseudomyxoma peritonei (PMP) is a rare condition characterized by extensive abdominal mucin accumulation.
- Recent research links PMP to appendiceal adenomas or adenocarcinomas, differentiating it from ovarian tumors.
- Histological subtypes, diffuse peritoneal adenomucinosis (DPAM) and mucinous peritoneal carcinomatosis (MPC), have distinct prognoses.
Purpose of the Study:
- To elucidate the origins and pathological distinctions of PMP.
- To compare the prognostic outcomes of DPAM and MPC.
- To evaluate current and potential treatment modalities for PMP.
Main Methods:
- Review of pathological and genetic findings in PMP cases.
- Histological classification differentiating DPAM and MPC.
- Analysis of survival data based on PMP subtype and treatment.
Main Results:
- PMP originates from appendiceal adenomas (DPAM) or adenocarcinomas (MPC).
- DPAM has a more favorable prognosis compared to MPC.
- Supra-radical surgery offers a 5-year survival of 50-70%, with better outcomes for DPAM.
Conclusions:
- Histological differentiation between DPAM and MPC is key for PMP management.
- Aggressive surgical resection is the primary treatment for both PMP subtypes.
- Intraperitoneal chemo-hyperthermia is a potentially beneficial adjunct therapy for PMP.